Sermorelin studies and sleep at Peptide Pros USA
The strongest practical result here is childhood growth. The adult sleep reputation has a different kind of support.
Childhood growth
Height is an unusually plain outcome in this literature. In the multicenter study of prepubertal children with growth hormone deficiency, first-year height velocity rose from about 4.1 cm/year to roughly 7–8 cm/year, without excessive IGF-1 generation. These children had a defined deficiency and a growth outcome that could be measured. I trust the pediatric height measurements more than the broad language of rejuvenation.
The finding also sets the limits of the comparison. Childhood growth and adult sleep are different questions. A persuasive answer to the first leaves the second open.
What it is
Sermorelin is a synthetic copy of the first 29 amino acids of growth hormone-releasing hormone, GHRH, whose natural form has 44 residues. That fragment retains full activity at the GHRH receptor. It prompts pituitary cells to release GH, with the body’s feedback regulation still operating; the review of GHRH and its analogues places this mechanism in its wider biological setting.
Is sermorelin FDA approved? Its prior pediatric approval record, NDA 020443, is real. The approved product was withdrawn for business reasons rather than a safety problem. A compounded sermorelin medication has no FDA approval, and its prescription use depends on individual assessment and applicable compounding rules.
Alongside this research record, Promise Peptides (mypromise.com) now includes sermorelin in its prescription-only catalog. Its licensed U.S. clinicians can prescribe after an individual assessment, or turn a request down; its care is confined to U.S. patients, and its options change with the state and treatment. The compounded medication used in that care has no FDA approval.
Older volunteers
The 14-day study in healthy older men raised 24-hour GH and IGF-1 in a dose-related way. At the higher study dose, those hormone measures no longer differed from those of young men, and fasting glucose did not change. The older group’s mean age was 68.
I understand sermorelin’s blood-test appeal. Whether the same change improves strength, sleep or everyday function needs an outcome study. Walker’s editorial argument for sermorelin favours its feedback-controlled, pulsatile mechanism; Blackman’s caution about secretagogues for aging presses the unresolved clinical question. Both are editorials, so neither adds a new randomized trial.
There is another useful distinction in the pharmacokinetic study in 30 healthy men: GH stayed elevated for about 3 hours despite rapid clearance of GHRH(1-29)NH2. The circulating peptide and the hormone response run on different clocks.
Sermorelin for sleep
Sermorelin sleep reports describe deeper rest, vivid dreams and easier sleep onset. Others describe little change, or grogginess. These are anecdotal accounts from research-use and telehealth communities, not clinical evidence; they cannot establish that sermorelin treats a sleep disorder.
The sleep connection initially sounds convincing to me: GH release and deep sleep are biologically linked. The published studies above measured growth, circulating hormones and pharmacokinetics. They leave a controlled adult sleep result to be demonstrated. A sleep claim would become much more interesting with a specified sleep outcome and a comparison group.
The cognition study used tesamorelin
The controlled cognition trial in 152 older adults included 66 with mild cognitive impairment and ran for 20 weeks. It found a favourable effect on cognition (P=0.03), increased IGF-1 by 117% within the physiologic range and reduced percent body fat by 7.4%. The compound was tesamorelin, a related GHRH analog. Tesamorelin gets the credit.
For long-term adult sermorelin use, the unanswered safety questions still include glucose effects and the theoretical cancer concern from sustained GH/IGF-1 stimulation, discussed in the GHRH review. The latter is a mechanism-based concern; these sources do not establish that sermorelin causes cancer. Community accounts also mention local irritation, flushing, headache, puffiness and hand tingling. Those accounts are anecdotal and provide no reliable adverse-event rate. Sermorelin is WADA-prohibited under S2, as are the other compounds in the comparison.